Health ❯ Healthcare ❯ Cancer Treatment

Combination Therapy

Revumenib Giredestrant and Everolimus Pertuzumab (Perjeta) Synergistic Effects Molecular Pathways Anti-PD-1 Therapy Drug Interactions Chemotherapy Immunotherapy Drugs Venetoclax and HMA Kinase Inhibitors Targeted Therapy KRAS Mutations

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Investigators reported early MRD clearance without added toxicity in an elderly cohort.

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

mRNA Neoantigen Vaccine Amplifies Anti-PD-1 Immunity and Suppresses Gastric Cancer Spread in Mice

Universal mRNA Vaccine Eradicates Tumors in Mice and Advances Toward Human Trials

FDA Clears MT-125 for First Human Trials in Treatment-Resistant Glioblastoma

Triplet Therapy Doubles Survival in BRAF V600E Metastatic Colorectal Cancer